# Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis

> **NCT01590966** · PHASE3 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 41 (actual)

## Conditions studied

- Axial and Peripheral Spondyloarthritis
- Rheumatoid Arthritis

## Interventions

- **DRUG:** administration of Cimzia®
- **DRUG:** Immunoscintigraphy with radiolabeled Cimzia®.

## Key facts

- **NCT ID:** NCT01590966
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-18
- **Primary completion:** 2019-03-26
- **Final completion:** 2019-08-20
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590966, "Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01590966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*